1
|
Malik AH, Yandrapalli S, Goldberg M, Jain D, Frishman WH, Aronow WS. P2484SGLT2 inhibitors in diabetes with CKD. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
DM mellitus (DM) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular morbidity and mortality. Current guideline recommendations do not support the use of SGLT2 inhibitors in patients with CKD stage III or higher. We performed a comprehensive meta-analysis to evaluate their cardiovascular effects in patients with type 2 DM and CKD stage III or higher.
Methods
A comprehensive search was performed in PubMed, Cochrane central and Embase for randomized controlled trials (RCTs) evaluating the cardiovascular outcomes of SGLT-2 inhibitors in patients with type 2 DM and CKD defined as glomerular filtration rate of <60ml/min. There were no data available on patients with end-stage renal disease. We calculated treatment effects and associated standard errors from the corresponding odds ratio and confidence interval. These values were imputed in software R to perform meta-analysis via generic inverse variance method. Additionally, we conducted a network meta-analysis to compare the relative efficacy and safety of each agent.
Results
Data from 7 RCTs and 6,527 participants was available. In patients with type 2 DM and CKD, SGLT-2 inhibitor use resulted in a significant reduction of myocardial infarction (22%), heart failure hospitalization (39%), and major adverse cardiac events (20%) (all p-value<0.05). There was also a trend towards a reduction in stroke and cardiovascular mortality. In a network meta-analysis, canagliflozin was the most effective in reduction of MI, stroke and heart failure hospitalization. Empagliflozin performed better for the outcome of cardiovascular mortality, but the results failed to reach significance.
Conclusion
SGLT-2 inhibitors significantly improve cardiovascular outcomes in patients with type 2 DM and CKD stage III or higher. This meta-analysis confirms that renal dysfunction should not be a deterrent to the widespread utilization of SGLT-2 inhibitors. Further studies are needed to identify the mechanisms behind these improved cardiovascular outcomes
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- A H Malik
- New York Medical College, Internal medicine, Valhalla, United States of America
| | - S Yandrapalli
- New York Medical College, New York, United States of America
| | - M Goldberg
- New York Medical College, New York, United States of America
| | - D Jain
- New York Medical College, New York, United States of America
| | - W H Frishman
- New York Medical College, Internal medicine, Valhalla, United States of America
| | - W S Aronow
- New York Medical College, Internal medicine, Valhalla, United States of America
| |
Collapse
|
2
|
Black HR, Chrysant SG, Curry CL, Frishman WH, Grimm RH, Lasseter KC, Okun R, Pool JL, Raizada V, Vlachakis ND. Antihypertensive and Metabolic Effects of Concomitant Administration of Terazosin and Methyclothiazide for the Treatment of Essential Hypertension. J Clin Pharmacol 2013; 32:351-9. [PMID: 1349028 DOI: 10.1002/j.1552-4604.1992.tb03847.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The efficacy and safety of once-daily 2.5- or 5.0-mg methyclothiazide (MCTZ) added to once-daily 5.0-mg terazosin (TRZ) versus 5.0-mg TRZ alone was evaluated in this double-blind, multicenter study. All patients received TRZ during a 6-week titration period. Hypertensive patients (222) (mean blood pressure of 159/104 mm Hg) were randomized to one of three treatment groups: TRZ alone (N = 76); TRZ+MCTZ-2.5 mg (N = 74); and TRZ+MCTZ-5.0 mg (N = 72) for the 8-week double-blind period. Changes in the supine and standing SBP/DBP from preTRZ period were: TRZ alone (-4.8/-8.1 and -2.6/-6.1 mm Hg); TRZ+MCTZ-2.5 mg (-17.3/-12.4 and -16.0/-11.2 mm Hg); and TRZ+MCTZ-5.0 mg (-20.6/-14.4 and -23.3/-14.6 mm Hg). Blood pressure changes in the combination groups were significantly greater than those in the TRZ alone group. However, there were no statistically significant differences between the TRZ+MCTZ-2.5-mg and TRZ+MCTZ-5.0-mg groups. The combination of TRZ and MCTZ tends to mitigate the adverse effects on serum glucose, uric, potassium and lipids usually associated with thiazide diuretics. Thus, combination treatment that begins with TRZ and adds MCTZ is effective in lowering blood pressure without any significant adverse metabolic effects.
Collapse
|
3
|
Frishman WH, Gomberg-Maitland M, Hirsch H, Catanese J, Furia-Palazzo S, Mueller H, Steingart R, Forman S. Differences between male and female patients with regard to baseline demographics and clinical outcomes in the Asymptomatic Cardiac Ischemia Pilot (ACIP) Trial. Clin Cardiol 2009; 21:184-90. [PMID: 9541762 PMCID: PMC6655608 DOI: 10.1002/clc.4960210310] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Coronary artery disease (CAD) is a common problem in men and women; however, men and women with similar clinical presentations of myocardial ischemia may receive different revascularization treatments. HYPOTHESIS Using the data base of the Asymptomatic Cardiac Ischemia Pilot (ACIP) trial, this study was undertaken to compare by gender the baseline demographic data and the clinical outcome results in patients randomized to various treatments in the ACIP study. METHODS This randomized trial compared three treatment regimens [pharmacologic management of angina, pharmacologic management of angina and ambulatory electrocardiographic (ECG) evidence of ischemia, and revascularization--that is, angioplasty and coronary artery bypass surgery], in patients with known CAD, positive stress ECG tests, and ECG evidence of ischemia during 48 h ambulatory monitoring. In all, 558 patients were randomized, 79 of whom were women (mean age: men 61.6 years, women 60.6 years) Ambulatory ECG evidence of ischemia, clinical events, that is, death, myocardial infarction, hospital admission for coronary events, and exercise performance were monitored. RESULTS Although of the same age as men at baseline, women had a higher prevalence of hypertension and diabetes. Women had less severe CAD by angiography and higher left ventricular ejection fractions. Men had longer exercise tolerance times on the treadmill. However, men and women had similar numbers and duration of ambulatory ECG ischemic abnormalities. Regarding revascularization, men more commonly underwent coronary artery bypass surgery (p = 0.025) while women underwent percutaneous transluminal coronary angioplasty more frequently (p = 0.10). Clinical outcomes were comparable in men and women, although the numbers of events were relatively small. CONCLUSIONS Men and women of comparable age manifest CAD with similar ischemic ECG abnormalities seen on both exercise tolerance and ambulatory ECG examinations. In ACIP, women tended to have more risk factors for CAD and less severity in anatomical disease, which may explain why women are less likely than men to have coronary bypass surgery.
Collapse
Affiliation(s)
- W H Frishman
- Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Frishman WH, Bittar N, Glasser S, Habib G, Smith W, Pordy R. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris. Clin Cardiol 2009; 21:483-90. [PMID: 9669057 PMCID: PMC6656231 DOI: 10.1002/clc.4960210707] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Mibefradil, a newly approved antihypertensive and antianginal drug, is the first member of a new class of calcium antagonists (CAs), the tetralol derivatives, that selectively blocks T-type Ca2+ channels in contrast to classical CAs which, at therapeutic concentrations, block only L-type Ca2+ channels. Since patients with chronic stable angina pectoris typically may be treated with the combination of a long-acting nitrate and a CA, the additive efficacy and safety of mibefradil in combination with nitrate therapy needs to be determined. HYPOTHESIS This study was designed to assess the efficacy, tolerability, and safety of mibefradil when added to long-acting nitrate therapy in patients with chronic stable angina pectoris. METHODS Following a 1-week placebo run-in period, patients were randomized to receive either mibefradil 50 mg (n = 96) or placebo (n = 93) once daily in addition to their nitrate therapy. After 2 weeks of active treatment, patients receiving the mibefradil were force titrated to 150 mg once daily for an additional 2 weeks. Exercise tolerance tests (ETTs) were performed at the end of Weeks 2 and 4; patients also maintained an anginal diary during the 4-week treatment period. RESULTS After 2 weeks of treatment with 50 mg mibefradil (within the current recommended dose range), a statistically significant but modest increase in total exercise duration was observed (treatment effect 16.4 s, p = 0.04). Similarly, there was a significant increase in time to onset of ischemia (treatment effect 26 s, p = 0.008). The adverse event profile of the 50 mg dose was indistinguishable from placebo, indicating that this dose was extremely well tolerated. At Week 4, the mibefradil-treated patients were taking 150 mg, which is above the current recommended dose range. The increase in total exercise duration was larger for the mibefradil 150 mg group than for the placebo group. For the intent-to-treat population, this difference did not reach statistical significance, whereas in the standard population it did (treatment effect 21 s, p = 0.05). The other two ETT variables, time to onset of angina and time to onset of 1 mm ST-segment depression, demonstrated significantly greater effect with mibefradil 150 mg (treatment effects 40 s, p = 0.002, and 55 s, p < 0.001, respectively, for the intent-to-treat population). Mibefradil 150 mg was associated with more adverse events than placebo, specifically, dizziness, leg edema, and postural hypotension. CONCLUSIONS This study demonstrates that mibefradil 50 mg once daily in the setting of the background long-acting nitrate therapy produces additive antianginal and anti-ischemic effects and is extremely well tolerated.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
| | | | | | | | | | | |
Collapse
|
5
|
Frishman WH, Veresh M, Schlocker SJ, Tejani N. Pathophysiology and medical management of systemic hypertension and pre-eclampsia in pregnancy. Minerva Med 2006; 97:347-64. [PMID: 17008838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Hypertension in pregnancy includes a group of distinct disorders that require special consideration in both prevention and pharmacological treatment. In recent years, there have been few advances regarding the pathophysiology and prevention of pre-eclampsia, however there have been some promising studies regarding possible modes of screening women for preeclampsia before clinical signs and symptoms are apparent. The recommendations for first-line drug therapy for the hypertensive complications of pre-eclampsia, and the recommendations for pharmacological treatment of women with chronic hypertension antedating pregnancy, have changed little primarily because first-line medications have the advantage of having had more extensive research experience. Recent clinical trials have demonstrated the efficacy and safety of various second-line drugs for the hypertensive disorders of pregnancy; whether these therapies can eventually replace the standard recommended medications will require more extensive long-term investigation.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA.
| | | | | | | |
Collapse
|
6
|
|
7
|
|
8
|
Abstract
Tobacco smoking is associated with an increased risk for the development of coronary and pulmonary vascular diseases and smoking cessation will greatly reduce this risk. Nicotine replacement and nonnicotine modalities have been used alone and in combination to help in smoking cessation. These treatment modalities appear to be safe in patients with known stable coronary artery disease.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA
| | | | | |
Collapse
|
9
|
Black HR, Elliott WJ, Weber MA, Frishman WH, Strom JA, Liebson PR, Hwang CT, Ruff DA, Montoro R, DeQuattro V, Zhang D, Schleman MM, Klibaner MI. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension 2001; 38:1118-23. [PMID: 11711508 DOI: 10.1161/hy1101.095000] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Asubstantial number of older hypertensive patients have stage 1 isolated systolic hypertension (systolic blood pressure between 140 and 159 mm Hg and diastolic blood pressure <90 mm Hg), but there are currently no data showing that drug treatment is effective, safe, and/or beneficial. To compare the effects of active treatment compared with placebo on blood pressure, left ventricular hypertrophy, and quality of life among older stage 1 isolated systolic hypertensive patients, a randomized, double-blind, parallel-group, multicenter clinical trial comparing felodipine (2.5, 5, or 10 mg once daily) and matching placebo was performed in 171 patients (49% male, average age 66+/-7 years, with 49% white and 30% Hispanic) with a baseline blood pressure of 149+/-7/83+/-6 mm Hg. During 52 weeks of treatment, patients randomized to active treatment achieved significantly lower blood pressures (137.0+/-11.7/80.2+/-7.6 mm Hg for extended-release felodipine versus 147.5+/-16.0/83.5+/-9.7 mm Hg for placebo, P<0.01 for each), a reduced incidence of left ventricular hypertrophy (7% for extended release felodipine versus 24% for placebo, P<0.04), and improved quality of life (change in Psychological General Well-Being index, 3.0+/-6.8 for extended-release felodipine versus -0.8+/-10.3 for placebo, P<0.01) versus baseline. There were no clinically significant differences between treatments in tolerability or adverse effects. Stage 1 isolated systolic hypertension can be effectively and safely treated pharmacologically. Treatment reduced progression to the higher stages of hypertension, reduced the incidence of left ventricular hypertrophy, and improved an overall measure of the quality of life. Larger and longer studies will be needed to document any long-term reduction in cardiovascular event rates associated with treating stage 1 systolic hypertension.
Collapse
Affiliation(s)
- H R Black
- Department of Preventive Medicine, Rush Medical College of Rush University at Rush-Presbyterian-Saint Luke's Medical Center, Chicago, Illinois, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Nawarskas J, Rajan V, Frishman WH. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Heart Dis 2001; 3:378-85. [PMID: 11975822 DOI: 10.1097/00132580-200111000-00006] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Vasopeptidase inhibitors represent a new class of cardiovascular drugs. They function as a combined angiotensin-converting enzyme (ACE) inhibitor and neutral endopeptidase (NEP) inhibitor, the latter of which potentiates the actions of atrial natriuretic peptide (ANP) by minimizing its degradation in the circulation. The consequence of such dual inhibition is a synergistic reduction of vasoconstriction and enhancement of vasodilation, thereby serving to more effectively reduce blood pressure. Furthermore, inhibition of the renin-angiotensin-aldosterone system (RAAS) prevents physiologic compensatory responses in vivo seen with NEP inhibition alone. Vasopeptidase inhibitors have also shown to potentiate bradykinin and adrenomedullin, which additionally contribute to cardiovascular regulation. The most extensively researched and promising agents within the class of VP inhibitors is omapatrilat, a mercaptoacyl derivative of a bicyclic thiazepinone dipeptide. It is a single molecule with equal potency and affinity for ACE and NEP inhibition. Although ACE inhibition tends to more selectively benefit high-renin models of hypertension, vasopeptidase inhibition has been shown to be equally efficacious in low-, normal-, and high-renin models. Contrary to NEP inhibition alone, omapatrilat has also demonstrated the ability to significantly reduce blood pressure in spontaneously hypertensive rats, the equivalent of essential hypertension in humans. Studies also suggest that omapatrilat has cardioprotective properties, especially in the setting of congestive heart failure. More specifically, animal models have demonstrated omapatrilat to be more effective than ACE inhibition alone in remodeling the heart and improving its contractile function. Human studies have documented the efficacy of omapatrilat in the treatment of both hypertension and, to a lesser extent, heart failure. Safety concerns (specifically angioedema) are currently being addressed before the widespread utilization of this promising new agent.
Collapse
Affiliation(s)
- J Nawarskas
- Department of Pharmacy, University of New Mexico, Albuquerque, NM, USA
| | | | | |
Collapse
|
11
|
Frishman WH, Kowalski M, Nagnur S, Warshafsky S, Sica D. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. Heart Dis 2001; 3:386-97. [PMID: 11975823 DOI: 10.1097/00132580-200111000-00007] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Glaucoma and ocular hypertension are highly prevalent conditions in individuals over the age of 40 and are commonly seen together in patients with cardiovascular disease. Many of the antiglaucoma medications, when systemically absorbed, affect the sympathetic and parasympathetic nervous systems of patients and can cause cardiovascular toxicity. Such adverse effects are frequently associated with the long-term use of potentially toxic agents in elderly people, who are most prone to chronic eye disease. Moreover, patients may not associate their symptoms with the topical eye medications, and consequently may not report adverse drug effects. Drug-drug interactions can also occur when patients are taking medications for both cardiovascular disease and glaucoma. This review focuses on beta-adrenergic blockers as topical antiglaucoma medications and other topical antiglaucoma drugs. The systemic toxicity of these agents is reviewed, along with the possible drug interactions. Brief mention is also made of other antiglaucoma medications used alone and in combination with topical beta-blockers.
Collapse
Affiliation(s)
- W H Frishman
- Departments of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
| | | | | | | | | |
Collapse
|
12
|
Affiliation(s)
- W H Frishman
- New York Medical College/Westchester Medical Center,Valhalla, New York, USA
| |
Collapse
|
13
|
Abstract
Bradykinin is a vasoactive kinin known to be involved in many biologic processes. Levels of bradykinin have been shown to be elevated in a number of cardiac diseases. It is thought that these elevated levels play a protective role in cardiovascular diseases. Preliminary studies have demonstrated that bradykinin may have beneficial effects on a wide spectrum of cardiovascular disorders. Though much study is still required, bradykinin augmentation represents an exciting new target for the treatment of cardiovascular disease.
Collapse
|
14
|
Abstract
Tumor necrosis factor (TNF) is a proinflammatory cytokine that can produce widespread deleterious effects when expressed in large amounts. It is produced in the heart by both cardiac myocytes and resident macrophages under conditions of cardiac stress, and is thought to be responsible for many of the untoward manifestations of cardiac disease. This article discusses the role of TNF in heart disease and some potential therapeutic modalities that can influence the cytokine activity. The results of controlled studies would suggest that TNF inhibition does not influence the clinical course of patients with heart failure.
Collapse
Affiliation(s)
- A S Retter
- Department of Internal Medicine, Temple University Hospital, Philadelphia, Pennsylvania 19004, USA
| | | |
Collapse
|
15
|
Guttenplan N, Lee C, Frishman WH. Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: focus on caspase inhibition. Heart Dis 2001; 3:313-8. [PMID: 11975812 DOI: 10.1097/00132580-200109000-00007] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Apoptosis is a type of programmed cell death that is evident during embryonic development and normal tissue turnover. When the apoptotic activity extends beyond physiologic limits, it can determine and/or contribute to those pathologic states characterized by excessive cell loss and impairment of organ function. The clinical development of caspase inhibitors may represent a potential therapeutic strategy for influencing the onset and progression of ventricular dysfunction to terminal failure. This article focuses on the caspase cascade, a fundamental enzymatic system for apoptotic cell death. Caspases do not constitute the death signals, but are implicated in their transmission. These cytoplasmic cysteine proteases have a dual role in apoptosis. Caspases can operate as initiators, activating an endonuclease that catalyzes deoxyribonucleic acid fragmentation. Alternatively, caspases can act as effectors, participating in the total disassembly of cell structures. For example, apoptosis represents the principal form of myocyte death in the region of an acute myocardial infarction. In addition, apoptosis in the region bordering the infarct can influence the development of ischemic cardiomyopathy and ventricular dilation.
Collapse
Affiliation(s)
- N Guttenplan
- Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
| | | | | |
Collapse
|
16
|
Abstract
Inflammation-related processes play a key role the current etiologic model of atherosclerosis and its acute complications. Recent evidence suggests that blood-based biomarkers that reflect systemic inflammation may contribute to our ability to predict future risk of cardiovascular disease. Global markers of inflammation, such as C-reactive protein and fibrinogen, have been well studied as potential cardiovascular risk factors. A variety of additional markers that reflect various elements of the complex systems governing inflammation, including proinflammatory and antiinflammatory cytokines, mediators of cellular adhesion, and matrix degradation enzymes, are also worthy of study. Although many previous studies have examined the relation of inflammation to myocardial infarction, emerging evidence suggests that other cardiovascular phenotypes such as ischemic stroke and early-stage atherosclerosis may also be related to inflammation. Further elucidating the role of inflammation in cardiovascular disease may lead to the identification of new targets for preventive or therapeutic interventions. In addition, markers of inflammation may be useful as a means to predict or monitor an individual's response to currently available cardiovascular therapies, such as aspirin or HMG coenzyme A reductase inhibitors, that may act via antiinflammatory mechanisms.
Collapse
Affiliation(s)
- R C Kaplan
- Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
| | | |
Collapse
|
17
|
Abstract
Thrombotic thrombocytopenic purpura is a rare complication of ticlopidine treatment. This syndrome has been reported to occur typically within the first few weeks after the initiation of therapy. The authors describe a case of a 72-year-old woman in whom thrombotic thrombocytopenic purpura developed just 2 days after starting ticlopidine therapy for a new-onset ischemic stroke. The patient responded successfully to plasmapheresis. The authors are reporting this case to emphasize the unpredictable nature of the association between the drug and the disease, which necessitates careful hematologic monitoring.
Collapse
Affiliation(s)
- N Naseer
- Divisions of General Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
| | | | | | | | | | | |
Collapse
|
18
|
Bueno EA, Mamtani R, Frishman WH. Alternative approaches to the medical management of angina pectoris: acupuncture, electrical nerve stimulation, and spinal cord stimulation. Heart Dis 2001; 3:236-41. [PMID: 11975800 DOI: 10.1097/00132580-200107000-00006] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Complementary or alternative modalities of medical treatment have been gaining attention as primary or supplementary therapies in cardiovascular disease pain management. However, definitive research in these areas has been limited by the inability to perform placebo-controlled trials when evaluating these treatments. Preliminary studies have suggested a possible benefit from acupuncture, electrical nerve stimulation, and spinal cord stimulation in the treatment of patients with angina pectoris and coronary artery disease.
Collapse
Affiliation(s)
- E A Bueno
- Department of Anesthesiology, Yale-New Haven Hospital, New Haven, Connecticut, USA
| | | | | |
Collapse
|
19
|
Abstract
Anthracyclines are important chemotherapeutic agents that are used for the treatment of various malignancies in both adults and children, but their usefulness has been limited by cardiotoxicity that is usually dose related. Oxidative injury appears to be the cause of myocardial dysfunction when using these drugs. Screening for early myocardial injury with troponin testing, echocardiography, and radionuclide examinations has reduced the incidence of chronic cardiac dysfunction. Various anthracycline analogues have been developed that have less cardiotoxicity. Dexrazoxane, an iron chelator, and the radioprotective agent amifostine protect against cardiac injury, thus allowing the use of higher doses of anthracyclines. Other strategies that have been evaluated are dietary glutamine supplementation and the use of the antioxidant probucol.
Collapse
Affiliation(s)
- M A Nelson
- Department of Medicine, the Albert Einstein College of Medicine, Bronx, New York, USA
| | | | | | | | | |
Collapse
|
20
|
Abstract
Endothelins, a family of peptides derived from the vascular endothelium and smooth muscle cells possess vasoconstrictor and mitogenic properties. By acting predominantly in a paracrine fashion, these peptides activate specific receptors and have protean effects in normal and diseased organ systems. The wide distribution of these receptors in various tissues mediate the multiplicity of physiologic actions attributed to endothelins. Much of our understanding about endothelins has come from the development of an array of receptor-specific and mixed receptor antagonists. Based on the promising results from animal studies, active research and drug development programs are under way to investigate the clinical potential of endothelin antagonism for treatment of cardiovascular disease.
Collapse
Affiliation(s)
- S Kaur
- Division of General Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla 10595, USA
| | | | | | | | | |
Collapse
|
21
|
Frishman WH. The kidney in the pathophysiology and treatment of cardiovascular disease. Heart Dis 2001; 3:139. [PMID: 11975782 DOI: 10.1097/00132580-200105000-00001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Abstract
From 1981 to 1994, 69 fourth-year students at the Albert Einstein College of Medicine participated in a 6-month medical school research project (MSRP) with the same mentor. Students could choose an original project or library project, and were required to prepare a written report suitable for submission to a peer-reviewed journal. In this article, it is assessed whether a mandatory fourth-year MSRP might substitute for traditional clinical electives. Student reactions to the experience were ascertained by using the responses to an open- and closed-ended questionnaire regarding skills gained by doing MSRPs, the impact on their careers, and their relationship to the mentor. Eighty-nine percent of the students responded that MSRPs increased their ability to formulate a hypothesis, 91% reported that this project increased their ability to conduct a literature search, 95% felt that MSRPs increased their knowledge of research techniques, and 91% reported having improved data collection skills after completing these projects. Students also reported that MSRPs increased their ability to critically evaluate the literature (95%) or to work independently (93%), and 89% responded that the project improved their ability to evaluate their individual strengths and weaknesses. Eighty-nine percent reported that the project increased their ability to write a research paper (34% of projects were original research, 35% were literature reviews, and 30% both original research and literature reviews). Thirty-three percent of respondents reported having some kind of problem completing their projects, and 90% of project reports were accepted for publication in peer-reviewed journals. Ninety-one percent of students responded that they had received appropriate guidance from their mentor, and 73% met with him at least once a week. Seventy-three percent described a relationship with the mentor that went beyond project advising. Eighty-five percent responded that the project impacted their careers in medicine, 97% felt that the research experience was a useful replacement for fourth-year electives, and 91% felt they were as well prepared for residency training as their classmates who had regular fourth-year electives without research. Fifty percent of students indicated that completion of an independent research project should not be required for graduation, whereas 18% responded it should be a requirement and 32% were undecided. Incorporating an MSRP in the fourth year appears to increase research skills and is considered to be a useful replacement for traditional elective rotations. The MSRP impacts favorably on future careers; however, many students do not think it should be a mandatory requirement for graduation from medical school.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, Epidemiology, and Social Medicine, The Albert Einstein College of Medicine, Bronx, New York, USA
| |
Collapse
|
23
|
Frishman WH. Management of unstable angina in 2001. Heart Dis 2001; 3:71-2. [PMID: 11975772 DOI: 10.1097/00132580-200103000-00001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Abstract
The survival rate of patients undergoing cardiopulmonary resuscitation is 5 to 15%. New cardiopulmonary resuscitation treatment approaches under investigation include the use of vasopressin as a vasopressor, amiodarone for the treatment of ventricular tachyarrhythmias, and adenosine antagonists (i.e., theophylline) for bradyasystolic rhythms. More innovative approaches include the use of thyroid hormone and endothelin.
Collapse
Affiliation(s)
- T Kelsch
- Department of Medicine, New York Medical College, Westchester County Medical Center, Valhalla, New York, USA
| | | | | | | |
Collapse
|
25
|
Frishman WH. Cardiopulmonary resuscitation 2000. Heart Dis 2001; 3:1. [PMID: 11975763 DOI: 10.1097/00132580-200101000-00001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Nayak DU, Karmen C, Frishman WH, Vakili BA. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease. Heart Dis 2001; 3:28-45. [PMID: 11975768 DOI: 10.1097/00132580-200101000-00006] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Oxygen-derived free radical formation can lead to cellular injury and death. Under normal situations, the human body has a free radical scavenger system (catalase, superoxide dismutase) that can detoxify free radicals. Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers have been used clinically to prevent the formation of oxidized LDL and to prevent reperfusion injury, which is often caused by free radicals. In this article, the pathogenesis of free radical production and cell injury are discussed, and therapeutic approaches for disease prevention are presented.
Collapse
Affiliation(s)
- D U Nayak
- Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York, USA
| | | | | | | |
Collapse
|
27
|
Frishman WH, Michelson EL. The ABC Trial. Heart Dis 2000; 2:389-91. [PMID: 11728288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
28
|
Frishman WH. ACE inhibitors and the arterial wall. Introduction. Postgrad Med 2000; 108:3. [PMID: 19667534 DOI: 10.3810/pgm.10.2000.suppl8.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- W H Frishman
- Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
| |
Collapse
|
29
|
Frishman WH. Increased vascular compliance/decreased cardiovascular risk: what the studies tell us. Heart Dis 2000; 2:384-8. [PMID: 11728287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Increasing arterial stiffness and decreasing arterial compliance are now thought to occur at the beginning of the hypertension disease process. Decreased arterial compliance is associated with isolated systolic blood pressure elevations. Many clinical trials of isolated systolic hypertension provide indirect evidence that improving compliance lowers the risk of cardiovascular disease. The Systolic Hypertension in the Elderly Program showed that antihypertensive therapy in older patients with isolated systolic hypertension lowers systolic blood pressure and narrows pulse pressure without unduly lowering diastolic blood pressure. Treatment over 5 years significantly reduced the incidence of stroke, nonfatal myocardial infarction and coronary death, all cardiovascular events, and all-cause mortality. The Systolic Hypertension in Europe and Systolic Hypertension in China trials showed similar effects on pulse pressure and on clinical end points. The Heart Outcomes Prevention Evaluation was a primary prevention study of the effect of an angiotensin-converting enzyme (ACE) inhibitor in subjects who were not necessarily hypertensive but were at risk for cardiovascular events. With minimal lowering of blood pressure, ramipril therapy provided significant risk reduction in all major end points--overall mortality, stroke, myocardial infarction, and cardiovascular death. ACE inhibitors restore endothelial cell balance to improve arterial compliance, thus they can provide benefits beyond lowering blood pressure.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, Munger Pavilion, Room 263, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA.
| |
Collapse
|
30
|
Abstract
The presence of multiple medical illnesses often distinguishes elderly patients with heart failure and can make pharmacologic management of symptomatic heart failure challenging in this population. Physiologic changes that occur with normal aging may complicate clinical assessment. Limited data from large clinical trials of heart failure therapy are applicable to aged patients. Available data suggest that elderly patients should be treated with the same regimen as younger patients but that more careful attention should be paid to dosing, especially when initiating a new drug. History and physical examination techniques can be used to uncover evidence of congestion and inadequate perfusion and are critical adjuncts when making therapeutic decisions. The objectives of therapy for elderly patients with heart failure must be individualized within the larger context of patients' goals and stage of life.
Collapse
Affiliation(s)
- N K Sweitzer
- Division of Cardiovascular Medicine, Department of Medicine, Brigham & Women's Hospital, Boston, Massachusetts, USA
| | | | | |
Collapse
|
31
|
Frishman WH. Management of systemic hypertension: current thoughts from clinical trials. Heart Dis 2000; 2:277. [PMID: 11794141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
32
|
Nelson MA, Passeri J, Frishman WH. Therapeutic angiogenesis: a new treatment modality for ischemic heart disease. Heart Dis 2000; 2:314-25. [PMID: 11728275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Angiogenesis is the process of new blood vessel formation, and has potential clinical use in the management of ischemic heart disease. A considerable amount of ongoing research has recently focused on the process of angiogenesis, including the identification of various factors that can inhibit or stimulate this process. The picture that is emerging suggests that a complex set of interactions involving various cells and cellular products is the key to angiogenesis. In particular, endothelial cells and growth factors, such as vascular endothelial growth factor and fibroblast growth factor, appear to play integral roles in angiogenesis. Various preclinical studies involving animal models of ischemia explored the potential use of angiogenesis in ischemic disease. Based on encouraging results, a number of clinical trials involving angiogenesis have been initiated to determine whether the process of angiogenesis also offers therapeutic benefit in humans.
Collapse
Affiliation(s)
- M A Nelson
- Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA
| | | | | |
Collapse
|
33
|
Lah JJ, Frishman WH. Adrenomedullin: a vasoactive and natriuretic peptide with therapeutic potential. Heart Dis 2000; 2:259-65. [PMID: 11728267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Adrenomedullin is a potent endogenous vasodilating and natriuretic peptide that is similar in structure to calcitonin gene-related peptide (CGRP). The gene involved in the synthesis of adrenomedullin has been localized to a single locus on chromosome 11, with specific sites on the genome to regulate transcription. Adrenomedullin is normally found in human plasma and in other organs. It is thought that one of the clearance sites for this peptide is in the pulmonary circulation. Endothelial cells are assumed to be one of the major sources of plasma adrenomedullin. Adrenomedullin is an important factor in regulating local and systemic vascular tone, by its activity as an autocrine/paracrine and circulating hormone. Depending on the site of action, adrenomedullin seems to bind to a CGRP receptor and send signals by either cyclic adenosine monophosphate or nitric oxide. From the results of experiments in animals, it has become clear that adrenomedullin's effects are species-specific. However, what is commonly seen with adrenomedullin is peripheral vasodilatation, a positive inotropic action, increased cardiac output, and increased stroke volume. In addition, adrenomedullin has actions in the brain, lungs, and kidneys to regulate regional hemodynamics. With these activities defined, recent studies have suggested a potential therapeutic role for adrenomedullin.
Collapse
Affiliation(s)
- J J Lah
- Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
| | | |
Collapse
|
34
|
Brosnan BD, Frishman WH, Sun DK, Grossman M. Adverse dermatologic effects of cardiovascular drug therapy. Heart Dis 2000; 2:220-47. [PMID: 11728264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Cardiovascular disease is common, affecting an increasing number of persons as the population ages. To combat this growing health problem, physicians use a multitude of medications in the treatment of their patients. Although pharmacologic therapy greatly enhances quality of life for a majority of patients, there is always the potential for an unfavorable reaction. For example, cardiovascular drugs can induce a vast array of adverse dermatologic responses. This article reviews the various cutaneous reaction patterns that can occur as a result of treatment with specific cardiovascular agents.
Collapse
Affiliation(s)
- B D Brosnan
- Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
| | | | | | | |
Collapse
|
35
|
Frishman WH. Angiotensin-converting enzyme inhibitors for the prevention and treatment of cardiovascular disease. Heart Dis 2000; 2:183-4. [PMID: 11794142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
36
|
Affiliation(s)
- W H Frishman
- Department of Medicine, New York Medical College, New York, New York, USA
| |
Collapse
|
37
|
Abstract
Serotonin is a naturally occurring vasoactive substance that has diverse cardiophysiological effects. These effects can be explained by the existence of serotonin receptor subtypes which mediate different biological actions. The vasoconstrictive actions of serotonin are mediated by 5-HT2 serotonergic receptors, and serotonin also amplifies the release and activities of other vasoconstrictors, such as angiotensin and norepinephrine. Abnormalities in the serotonergic system may play an important role in the pathophysiology of multiple cardiovascular disease states such as systemic hypertension, primary pulmonary hypertension and peripheral vascular disease. Selective 5-HT2 serotonergic receptor blockers have been developed which appear to be potent vasodilators with therapeutic potential in various cardiovascular disease states. The largest clinical experience has been collected with ketanserin, and other agents in this class are being investigated. Prolongation of the ECG QT interval with 5-HT2 serotonergic receptor blockers may pose a potential risk with these treatments in some patients.
Collapse
Affiliation(s)
- W H Frishman
- Department of Medicine, New York Medical College, Valhalla 10595, USA.
| | | |
Collapse
|
38
|
Leri A, Kajstura J, Li B, Sonnenblick EH, Beltrami CA, Anversa P, Frishman WH. Cardiomyocyte aging is gender-dependent: the local IGF-1-IGF-1R system. Heart Dis 2000; 2:108-15. [PMID: 11728247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
To determine whether insulin-like growth factor 1 (IGF-1) and its receptor (IGF-1R) are implicated in the aging process of the heart, and if their impact differs in the two genders, the expression of IGF-1, and extracellular alpha-subunit and transmembrane beta-subunit of IGF-1R was measured in left ventricular myocytes isolated from male and female Fischer 344 rats at 3, 8, 12, 16, and 26 months after birth. Additionally, the extent of myocardial damage in both sexes was evaluated in rats at 3 and 26 months by confocal microscopy. Finally, ventricular hemodynamics was assessed in the closed-chest preparation. From 3 to 26 months, aging was characterized by an 83%, 84% decrease and disappearance in the quantity of IGF-1, IGF-1Ralpha and IGF-1Rbeta in male myocytes. Corresponding changes in female myocytes were 40%, 28% and 43%. These molecular modifications at the myocyte level were coupled with tissue injury, consisting of multiple foci of replacement fibrosis across the left ventricular wall. However, myocardial fibrosis in females was 76% and 77% significantly less than in the young and old male heart, respectively. These multiple age-associated events were accompanied by cardiac decompensation in the senescent male rat, while modest indices of ventricular dysfunction were detected in old female rats. In conclusion, the enhanced IGF-1-IGF-1R system in female myocytes may condition the favorable outcome of age in this gender.
Collapse
Affiliation(s)
- A Leri
- Department of Medicine, Vosburgh Pavilion, Room 318, New York Medical College, Valhalla, NY 10595, USA
| | | | | | | | | | | | | |
Collapse
|
39
|
Awad K, Ali P, Frishman WH, Tejani N. Pharmacologic approaches for the management of systemic hypertension in pregnancy. Heart Dis 2000; 2:124-32. [PMID: 11728250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Hypertension in pregnancy includes a group of distinct disorders that require special consideration in both prevention and pharmacologic treatment. In recent years, there have been few advances regarding the pathophysiology and prevention of preeclampsia, or in recommendations for first-line drug therapy of the hypertensive complications of preeclampsia. Similarly, the recommendations for pharmacologic treatment of women with chronic hypertension antedating pregnancy have changed little, primarily because first-line medications have the advantage of having been the subjects of extensive research experience. Recent clinical trials have demonstrated the efficacy and safety of various second-line drugs for treating hypertensive disorders of pregnancy; whether these therapies can eventually replace the standard recommended medications will require more extensive long-term investigation.
Collapse
Affiliation(s)
- K Awad
- Department of Medicine, New York Medical College, Valhalla, NY 10595
| | | | | | | |
Collapse
|
40
|
Aronow WS, Frishman WH, Cheng-Lai A. Cardiovascular drug therapy in the elderly. Heart Dis 2000; 2:151-67. [PMID: 11728253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Cardiovascular diseases of various etiologies are most prevalent in the elderly, and there are many pharmacologic issues that need to be considered when prescribing drug therapies to this population. Aging itself alters the absorption, distribution, metabolism, and excretion of many drugs. Certain drugs, such as digoxin, lidocaine, and warfarin, need to be used with great caution in older patients because of a greater potential for drug toxicity. Elderly patients often are prescribed multiple drugs for different conditions, making them susceptible to major drug-drug interactions. Recommendations are provided to help ensure safe prescribing practices of cardiac drugs in older patients.
Collapse
Affiliation(s)
- W S Aronow
- Department of Geriatrics and Adult Development, Mt. Sinai Medical School, New York, NY, USA
| | | | | |
Collapse
|
41
|
Lerner RG, Frishman WH, Mohan KT. Clopidogrel: a new antiplatelet drug. Heart Dis 2000; 2:168-73. [PMID: 11728254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Clopidogrel is a new drug in the recently developed class of thienopyridine derivatives that inhibits platelet function by an inhibitory action exerted through the membrane adenosine diphosphate receptor. Clopidogrel is a prodrug that must be metabolized to an active metabolite in the liver. The basic chemistry, pharmacodynamics and pharmacokinetics of the drug are reviewed. Clinical trials with clopidogrel, including its use in patients with stents postangioplasty, adverse reactions, and potential advantages over other agents are summarized.
Collapse
Affiliation(s)
- R G Lerner
- Division of Hematology, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
| | | | | |
Collapse
|
42
|
Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000; 40:11-30. [PMID: 10631618 DOI: 10.1177/00912700022008649] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Hepatic impairment can alter the pharmacokinetic profiles of cardiovascular drugs, which can lead to unwanted toxicity. In the presence of cirrhosis, portosystemic shunting occurs and cytochrome P450 activity is reduced. Impaired oxygen uptake caused by changes in the liver's sinusoids, as proposed by the oxygen limitation theory, may also explain the alteration of drug metabolism seen in cirrhosis. With congestive heart failure, sinusoidal congestion and hypoperfusion of the liver are seen. Similar to cirrhosis, the common pathway for hepatic damage in congestive heart failure seems to be liver hypoxia, which may explain the disease's effect on drug metabolism. Since routine hepatic function tests do not always relate to the liver's ability to eliminate drugs, existing guidelines for dosing cardiovascular drugs in patients with hepatic impairment are limited. This article provides guidance for dosing cardiovascular drugs in cirrhotic and heart failure patients based on available research data. Altered drug metabolism, especially in congestive heart failure, tends to be overlooked or not realized in clinical practice. Therefore, further research is needed in congestive heart failure to better elucidate safe prescribing patterns.
Collapse
Affiliation(s)
- S I Sokol
- Department of Medicine, Montefiore Medical Center, Bronx, New York, USA
| | | | | | | |
Collapse
|
43
|
Perlmutter JB, Frishman WH, Feinstein RE. Major depression as a risk factor for cardiovascular disease: therapeutic implications. Heart Dis 2000; 2:75-82. [PMID: 11728243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
This review was conducted to analyze the literature regarding the association between psychological depression and cardiovascular disease (CVD). The literature was reviewed through Medline and Psychlit. Articles were located using search terms such as depression, CVD, coronary artery disease, and cardiac risk factor. The search included articles from 1980 through 1999. Both the cross-sectional and prospective data suggest that psychological depression is a risk factor for and an aggravating factor of preexisting CVD. Proposed pathophysiologic mechanisms and therapeutic implications are discussed.
Collapse
Affiliation(s)
- J B Perlmutter
- Payne Whitney Clinic, Department of Psychiatry, New York Presbyterian Hospital Cornell Campus, 525 East 68th Street, New York, NY 10021, USA
| | | | | |
Collapse
|
44
|
Palkhiwala SA, Yu A, Frishman WH. Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure. Heart Dis 2000; 2:83-92. [PMID: 11728244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
The imidazoline receptors recently have been discovered to be involved in the central nervous system control of sympathetic outflow. A new class of centrally acting antihypertensive agents, the imidazoline receptor agonists (rilmenidine and moxonidine), have been developed to control blood pressure effectively without the adverse effects of sedation and mental depression that usually are associated with centrally acting antihypertensive agents. This new generation of centrally acting antihypertensive agents is highly selective for the imidazoline receptor but has a low affinity for alpha(2)-adrenergic receptors. The usefulness of these agents in the treatment of congestive heart failure has not been demonstrated.
Collapse
Affiliation(s)
- S A Palkhiwala
- Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA
| | | | | |
Collapse
|
45
|
Frishman WH. Recent clinical trials. Heart Dis 2000; 2:1-2. [PMID: 11794144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
46
|
Warshafsky S, Packard D, Marks SJ, Sachdeva N, Terashita DM, Kaufman G, Sang K, Deluca AJ, Peterson SJ, Frishman WH. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. J Gen Intern Med 1999; 14:763-74. [PMID: 10632823 PMCID: PMC1496862 DOI: 10.1046/j.1525-1497.1999.02109.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
OBJECTIVE To determine if 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in preventing fatal and nonfatal strokes in patients at increased risk of coronary artery disease. DESIGN Meta-analysis of randomized controlled trials. Clinical trials were identified by a computerized search of MEDLINE (1983 to June 1996), by an assessment of the bibliographies of published studies, meta-analyses and reviews, and by contacting pharmaceutical companies that manufacture statins. Trials were included in the analysis if their patients were randomly allocated to a statin or placebo group, and reported data on stroke events. Thirteen of 28 clinical trials were selected for review. Data were extracted for details of study design, patient characteristics, interventions, duration of therapy, cholesterol measurements, and the number of fatal and nonfatal stroke events in each arm of therapy. Missing data on stroke events were obtained by contacting the investigators of the clinical trials. MAIN RESULTS Among 19,921 randomized patients, the rate of total stroke in the placebo group was 2.38% (90% nonfatal and 10% fatal). In contrast, patients who received statins had a 1.67% stroke rate. Using an exact stratified analysis, the pooled odds ratio (OR) for total stroke was 0.70 (95% confidence interval [CI] 0.57, 0.86; p =.0005). The pooled OR for nonfatal stroke was 0.64 (95% CI 0.51, 0.79; p =.00001), and the pooled OR for fatal stroke was 1.25 (95% CI 0.71, 2.24; p =.4973). In separate analyses, reductions in total and nonfatal stroke risk were found to be significant only for trials of secondary coronary disease prevention. Regression analysis showed no statistical association between the magnitude of cholesterol reduction and the relative risk for any stroke outcome. CONCLUSIONS The available evidence clearly shows that HMG-CoA reductase inhibitors reduce the morbidity associated with strokes in patients at increased risk of cardiac events. Data from 13 placebo-controlled trials suggest that on average one stroke is prevented for every 143 patients treated with statins over a 4-year period.
Collapse
Affiliation(s)
- S Warshafsky
- Section of General Internal Medicine, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Frishman WH. Silent myocardial ischemia: is it a clinical entity that requires therapy? Heart Dis 1999; 1:263. [PMID: 11727678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
48
|
Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Drugs 1999; 58:579-87. [PMID: 10551431 DOI: 10.2165/00003495-199958040-00001] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The prevention and treatment of hypertension remain as major challenges for clinicians all over the world. The recently published Sixth Report of the Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI) uses evidence-based medicine in providing guidelines to aid clinicians in the prevention, detection and treatment of high blood pressure, including pharmacological approaches. Calcium antagonists are used widely for the treatment of hypertension, and JNC-VI focuses on specific situations where calcium antagonists could be considered as preferred treatments. There are a large number of calcium antagonists available, with a variety of pharmacodynamic and pharmacokinetic actions. Several sustained-release formulations of these drugs are also available. In terms of blood pressure control, calcium antagonists are more effective as antihypertensive treatments than beta-blockers, ACE inhibitors and angiotensin II receptor blockers in Black patients. The dihydropyridine calcium antagonists have been shown to reduce morbidity and mortality in elderly patients with isolated systolic hypertension. The rate-lowering calcium antagonists can be used as alternatives to beta-blockers in patients with coronary artery disease and hypertension. Calcium antagonists can be used as alternatives to ACE inhibitors in patients with hypertension and concomitant diabetes mellitus and/or renal disease. Some dihydropyridine calcium antagonists may be useful as alternatives to ACE inhibitors in patients with hypertension and systolic heart failure. Calcium antagonists appear to be extremely useful in patients with cyclosporin-induced hypertension, and in patients with hypertension and concomitant Raynaud's phenomenon and/or migraine. The rate-lowering agents can be used in patients with atrial tachyarrhythmias and hypertension. Clinicians should be aware of drug-drug interactions involving calcium antagonists, especially after the recent problems with mibefradil. Although retrospective studies have caused controversy regarding the safety of calcium antagonists in patients with hypertension, recent prospective studies have revealed no major safety concerns with these drugs.
Collapse
Affiliation(s)
- V Singh
- Department of Medicine, New York Medical College, Valhalla, USA
| | | | | |
Collapse
|
49
|
Frishman WH. Is coronary atherosclerosis an infectious disease? Heart Dis 1999; 1:189. [PMID: 11727677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
50
|
Weisen SF, Frishman WH, Aronson MK, Wassertheil-Smoller S. Self-rated health assessment and development of both cardiovascular and dementing illnesses in an ambulatory elderly population: a report from the Bronx Longitudinal Aging Study. Heart Dis 1999; 1:201-5. [PMID: 11720624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
As part of the Bronx Longitudinal Aging Study, a prospective, community-based study designed to assess risk factors for cardiovascular and cerebrovascular morbidity and mortality and all-cause dementia, the investigators sought to determine whether a self-rated health assessment (SRHA) could be used as an independent predictor of new cardiovascular events and dementia (Alzheimer type and multi-infarct). A population of elderly (mean age 79 years) outpatient, ambulatory, nondemented patients (n = 487, 65% women) participated in this longitudinal study. Clinical diagnoses were made according to established criteria. At baseline, participants were asked to rate their current SRHA as excellent, good, fair, or poor, and were evaluated annually for as long as 10 years. Baseline SRHA findings were related to development of cardiovascular events and dementia. The SRHA was reported as excellent by 45 patients (9.4%), good by 212 (44.4%), fair by 178 (37.3%), and poor by 42 (8.8%). Using a multivariate analysis, patients whose SRHA was poor were 4.5 times more likely than those whose SRHA was excellent to have a fatal cardiovascular event, 2.6 times more likely to have a nonfatal cardiovascular event, and 5.3 times more likely to develop Alzheimer type and multi-infarct dementia. Similar findings were observed with dichotomous SRHA responses (comparing excellent/good to fair/poor). In an elderly population, SRHA appears to be an independent predictor of future cardiovascular and cerebrovascular events and development of all-cause dementia, which has possible therapeutic implications for prevention and treatment.
Collapse
Affiliation(s)
- S F Weisen
- Department of Medicine, Columbia Presbyterian Medical Center, New York, New York, USA
| | | | | | | |
Collapse
|